Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use

This article has been Reviewed by the following groups

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2021.12.18.21267628: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: Ethical and governance approval for the study was granted by the Western Sydney Local Health District Human Research Ethics Committee (2020/ETH02426) and (2020/ETH00786) SARS-CoV-2 culture: Respiratory tract specimens that had detectable SARS-CoV-2 RNA by RT-PCR were cultured in vero E6 cells expressing transmembrane serine protease 2 (VeroE6/TMPRSS2; JCRB1819) as previously outlined (Supplementary Figure S2).15 Briefly, cell cultures were seeded at 1-3×104 cells/cm2 in Dulbecco’s minimal essential medium (DMEM, Lonza, Basel, Switzerland) supplemented with 9% foetal bovine serum (FBS, HyClone).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line AuthenticationContamination: Routine mycoplasma testing using RT-PCR was performed to exclude cell line mycoplasma contamination and culture work was undertaken under physical containment laboratory level 3 (PC3) biosafety conditions.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    Sequencing libraries were then sequenced with paired end 76 bp chemistry on the iSeq or MiniSeq (Illumina) platforms.
    MiniSeq
    suggested: None
    Bioinformatic analysis: Raw sequence data were processed using an in-house quality control procedure prior to further analysis as described previously.17,18 De-multiplexed reads were quality trimmed using Trimmomatic v0.36 (sliding window of 4, minimum read quality score of 20, leading/trailing quality of 5 and minimum length of 36 after trimming).19 Briefly, reads were mapped to the reference SARS-CoV-2 genome (NCBI GenBank accession MN908947.3) using Burrows-Wheeler Aligner (BWA)-mem version 0.7.1720, with unmapped reads discarded.
    Trimmomatic
    suggested: (Trimmomatic, RRID:SCR_011848)
    BWA)-mem
    suggested: None
    The GISAID and New South Wales (NSW) genomes were aligned with MAFFT v7.402 (FFT-NS-2, progressive method).
    MAFFT
    suggested: (MAFFT, RRID:SCR_011811)
    28 Graphs were generated using RStudio (version 3.6.1) and phylogenetic trees were constructed using the R package ggtree.
    RStudio
    suggested: (RStudio, RRID:SCR_000432)

    Results from OddPub: Thank you for sharing your data.


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.